- Home
- ANAB vs IIIV Comparison
ANAB vs IIIV Comparison
Compare ANAB & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- IIIV
- Stock Information
- Founded
- ANAB 2005
- IIIV 2012
- Country
- ANAB United States
- IIIV United States
- Employees
- ANAB N/A
- IIIV N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- ANAB Health Care
- IIIV Technology
- Exchange
- ANAB Nasdaq
- IIIV Nasdaq
- Market Cap
- ANAB 630.2M
- IIIV 720.4M
- IPO Year
- ANAB 2017
- IIIV 2018
- Fundamental
- Price
- ANAB $21.08
- IIIV $32.18
- Analyst Decision
- ANAB Buy
- IIIV Buy
- Analyst Count
- ANAB 10
- IIIV 6
- Target Price
- ANAB $48.00
- IIIV $34.33
- AVG Volume (30 Days)
- ANAB 515.2K
- IIIV 179.9K
- Earning Date
- ANAB 11-04-2025
- IIIV 11-17-2025
- Dividend Yield
- ANAB N/A
- IIIV N/A
- EPS Growth
- ANAB N/A
- IIIV N/A
- EPS
- ANAB N/A
- IIIV 5.56
- Revenue
- ANAB $123,164,000.00
- IIIV $248,271,000.00
- Revenue This Year
- ANAB $11.40
- IIIV N/A
- Revenue Next Year
- ANAB $8.17
- IIIV $3.86
- P/E Ratio
- ANAB N/A
- IIIV $7.78
- Revenue Growth
- ANAB 304.17
- IIIV 25.08
- 52 Week Low
- ANAB $12.21
- IIIV $20.42
- 52 Week High
- ANAB $39.50
- IIIV $33.44
- Technical
- Relative Strength Index (RSI)
- ANAB 47.97
- IIIV 59.50
- Support Level
- ANAB $17.11
- IIIV $29.87
- Resistance Level
- ANAB $24.07
- IIIV $31.21
- Average True Range (ATR)
- ANAB 1.49
- IIIV 0.94
- MACD
- ANAB -0.03
- IIIV 0.01
- Stochastic Oscillator
- ANAB 57.03
- IIIV 95.82
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.